References
- Kopala LC. Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand 1996; 94: 12–7
- Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58 Suppl 10: 55–62
- Keks NA. Minimizing the non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand 1996; 94: 18–24
- Schultz CS. New antipsychotic medications: More than old wine and new bottles. Bull Menninger Clin 2000; 64: 60–75
- Kane John. Olanzapine in the long-term treatment of schizophrenia. Br J Psychiatry 1999; 174 Suppl 37: 26–9
- Tollefson GD, Beasley CM, Jr, Tran PV, Street JS. Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–65
- Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002; 40: 630–9
- Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extra pyramidal side-effect of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68
- Peuskens J. Good medical practice in antipsychotic pharmacotherapy. Int Clin Psychopharmacol 1998; 13 Suppl 3: 535–41
- Gilbody S, Wahlbeck K, Adams C. Randomized controlled trials in schizophrenia: A critical perspective of the literature. Acta Psychiatr Scand 2002; 105: 243–51
- Beck P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand ;76 Suppl 1986; 326: 32–7
- Nicholson IR, Chapman JE, Neufeld RWJ. Variability in BPRS definitions of positive and negative symptoms. Schizophr Res 1995; 17: 177–85
- Ohlsen, R, Smith, S, Taylor, D, Pilowsky, L. The UKU Side-effect Rating Scale. In: R Ohlsen, Smith, S, Taylor, D, Pilowsky, L.. Antipsychotic medication review – Service guidelines. Sanders: Editor Martin Dunitz; 2003.
- Sharpiro S. Confounding by indication. Epidemiology 1997; 8: 110
- Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomised clinical trial. Pharmacoeconomics 1999; 15: 469–80
- Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 2001; 155: 230–3
- Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; 53: 313–9
- Esseck MS, Drake ER, Frank GR, McQuire GT. Randomized controlled trials in evidence-based mental health care: Getting the right answer to the right question. Schizophr Bul 2003; 29: 115–23